SeaCrest Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

SeaCrest Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,396	Closed	-$615K	–	656
2023 Q2	$615K	Sell	7,396 -3,168	-30%	-$265K	0.08%	270
2023 Q1	$805K	Buy	10,564 +273	+3%	+$22.7K	0.11%	209
2022 Q4	$854K	Buy	+10,291	New	+$833K	0.12%	191
2022 Q3	–	Sell	-1,283	Closed	-$95K	–	1546
2022 Q2	$95K	Buy	+1,283	New	+$96.3K	0.01%	883
2021 Q4	–	Sell	-1,778	Closed	-$224K	–	735
2021 Q3	$224K	Buy	1,778 +100	+6%	+$12.9K	0.03%	591
2021 Q2	$227K	Sell	1,678 -100	-6%	-$13.1K	0.03%	605
2021 Q1	$241K	Hold	1,778	–	–	0.03%	537
2020 Q4	$250K	Buy	+1,778	New	+$228K	0.04%	494
2019 Q2	–	Sell	-2,060	Closed	-$187K	–	1865
2019 Q1	$187K	Buy	2,060 +560	+37%	+$47.6K	0.03%	497
2018 Q4	$108K	Sell	1,500 -560	-27%	-$45.1K	0.02%	638
2018 Q3	$197K	Buy	2,060 +100	+5%	+$9.7K	0.03%	505
2018 Q2	$187K	Hold	1,960	–	–	0.03%	515
2018 Q1	$172K	Buy	1,960 +240	+14%	+$21.9K	0.03%	529
2017 Q4	$146K	Buy	+1,720	New	+$144K	0.03%	588

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

SeaCrest Wealth Management's XBI Position: Q3 2023 in Review

SeaCrest Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2023, closing a stake of 7,396 shares — an estimated $615K sold.

SeaCrest Wealth Management first reported a position in XBI in Q4 2017 and held it in 14 quarters. The position peaked at $854K in Q4 2022. 677 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

SeaCrest Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2023 after selling out during the quarter.
SeaCrest Wealth Management sold 7,396 State Street SPDR S&P Biotech ETF shares in Q3 2023, an estimated $615K.
SeaCrest Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and held it in 14 quarters.
SeaCrest Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $854K in Q4 2022.
677 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on SeaCrest Wealth Management's 13F filing for Q3 2023, filed 12 Oct 2023.